|
1
|
Ariotti C, Gabriel AF, Ribeiro JT, Martins MAT, Vargas PA, Pilar EFS, Castilho RM, Carrard VC, Wagner VP, Martins MD. PI3K/AKT/mTOR pathway activation in actinic cheilitis and lip squamous cell carcinomas. J Eur Acad Dermatol Venereol 2020; 34:e505-e506. [PMID: 32255224 DOI: 10.1111/jdv.16420] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Accepted: 03/24/2020] [Indexed: 11/28/2022]
Affiliation(s)
- C Ariotti
- Department of Oral Pathology, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| | - A F Gabriel
- Department of Oral Pathology, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| | - J T Ribeiro
- Department of Oral Pathology, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| | - M A T Martins
- Department of Oral Pathology, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.,Department of Oral Medicine, Porto Alegre Clinics Hospital (HCPA/UFRGS), Porto Alegre, Brazil
| | - P A Vargas
- Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil
| | - E F S Pilar
- Experimental Pathology Unit, Clinics Hospital of Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| | - R M Castilho
- Laboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA
| | - V C Carrard
- Department of Oral Pathology, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.,Department of Oral Medicine, Porto Alegre Clinics Hospital (HCPA/UFRGS), Porto Alegre, Brazil
| | - V P Wagner
- Department of Oral Pathology, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.,Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil
| | - M D Martins
- Department of Oral Pathology, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.,Department of Oral Medicine, Porto Alegre Clinics Hospital (HCPA/UFRGS), Porto Alegre, Brazil.,Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil.,Experimental Pathology Unit, Clinics Hospital of Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| |
Collapse
|
|
2
|
Ribeiro JT, Macedo LT, Curigliano G, Fumagalli L, Locatelli M, Dalton M, Quintela A, Carvalheira JBC, Manunta S, Mazzarella L, Brollo J, Goldhirsch A. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? Ann Oncol 2012; 23:547-555. [PMID: 21896541 DOI: 10.1093/annonc/mdr382] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Despite current trend of targeted therapy development, cytotoxic agents are a mainstay of treatment of patients with breast cancer. We reviewed recent advances in cytotoxic therapy for patients with metastatic breast cancer (MBC). MATERIALS AND METHODS Medline searches were conducted for English language studies using the term 'MBC' and 'cytotoxic drugs'. The data search was restricted to the period 2000-2011. RESULTS Several novel cytotoxic compounds, all microtubule inhibitors, have been approved for clinical use in MBC: (i) nab-paclitaxel, reported to improve tumour response and decrease hypersensitivity reactions in comparison with other taxanes; (ii) ixabepilone, shown to have clinical benefit in taxane- and anthracycline-resistant disease and (iii) eribulin, shown to improve overall survival in heavily pre-treated patients, when compared with best available standard treatment. Agents, such as larotaxel, vinflunine, trabectidin and formulations, including cationic liposomal paclitaxel or paclitaxel poliglumex, are currently under evaluation in phase II/III trials. CONCLUSION Toxicity and chemotherapy resistance are still major limitations in the treatment of patients with MBC. Further research into new cytotoxic compounds is needed in order to maximise benefit, whilst minimising toxicity.
Collapse
Affiliation(s)
- J T Ribeiro
- Division of Medical Oncology, University of Lisboa Medical School, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
| | - L T Macedo
- Division of Medical Oncology, Hospital de Clinicas, State University Medical School of Campinas, Campinas, Brazil
| | - G Curigliano
- Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy.
| | - L Fumagalli
- Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
| | - M Locatelli
- Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
| | - M Dalton
- Oxford University Medical School, Brasenose College, University of Oxford, Oxford, UK
| | - A Quintela
- Division of Medical Oncology, University of Lisboa Medical School, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
| | - J B C Carvalheira
- Division of Medical Oncology, Hospital de Clinicas, State University Medical School of Campinas, Campinas, Brazil
| | - S Manunta
- Sassari University Medical School, Ospedale S. Campus, Sassari, Italy
| | - L Mazzarella
- Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
| | - J Brollo
- Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
| | - A Goldhirsch
- Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
| |
Collapse
|